Cargando…

Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals()

PURPOSE: We aimed to evaluate the cost effectiveness of Favipiravir treatment versus standard of care (SC) in moderately to severely ill COVID-19 patients from the Saudi healthcare payer perspective. METHODS: We used the patient-level simulation method to simulate a cohort of 415 patients with moder...

Descripción completa

Detalles Bibliográficos
Autores principales: Alamer, Ahmad, Almutairi, Abdulaali R., Halloush, Shiraz, Al-jedai, Ahmed, Alrashed, Ahmed, AlFaifi, Mashael, Mohzari, Yahya, Almutairi, Malak, AlHassar, Fatimah, Howaidi, Jude, Almutairi, Wedad, Abraham, Ivo, Alkhatib, Nimer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930375/
https://www.ncbi.nlm.nih.gov/pubmed/36819111
http://dx.doi.org/10.1016/j.jsps.2023.02.003
_version_ 1784889035432394752
author Alamer, Ahmad
Almutairi, Abdulaali R.
Halloush, Shiraz
Al-jedai, Ahmed
Alrashed, Ahmed
AlFaifi, Mashael
Mohzari, Yahya
Almutairi, Malak
AlHassar, Fatimah
Howaidi, Jude
Almutairi, Wedad
Abraham, Ivo
Alkhatib, Nimer
author_facet Alamer, Ahmad
Almutairi, Abdulaali R.
Halloush, Shiraz
Al-jedai, Ahmed
Alrashed, Ahmed
AlFaifi, Mashael
Mohzari, Yahya
Almutairi, Malak
AlHassar, Fatimah
Howaidi, Jude
Almutairi, Wedad
Abraham, Ivo
Alkhatib, Nimer
author_sort Alamer, Ahmad
collection PubMed
description PURPOSE: We aimed to evaluate the cost effectiveness of Favipiravir treatment versus standard of care (SC) in moderately to severely ill COVID-19 patients from the Saudi healthcare payer perspective. METHODS: We used the patient-level simulation method to simulate a cohort of 415 patients with moderate to severe COVID-19 disease who were admitted to two Saudi COVID-19 referral hospitals: 220 patients on Favipiravir and 195 patients on SC. We estimated the incremental cost-effectiveness ratio (ICER) of Favipiravir versus SC in terms of the probability to be discharged alive from hospital and the mean time in days to discharge one patient alive. The model was performed twice: first, using unweighted, and second, using weighted clinical and economic data. Weighting using the inverse weight probability method was performed to achieve balance in baseline characteristics. RESULTS: In the unweighted model, base case (probabilistic) ICER estimates favored Favipiravir at savings of Saudi Riyal (SAR)1,611,511 (SAR1,998,948) per 1% increase in the probability of being discharged alive. As to mean time to discharging one patient alive, ICERs favored Favipiravir at savings of SAR11,498 (SAR11,125). Similar results were observed in the weighted model with savings using Favipiravir of SAR1,514,893 (SAR2,453,551) per 1% increase in the probability of being discharged alive, and savings of SAR11,989 (SAR11,277) for each day a patient is discharged alive. CONCLUSION: From the payer perspective, the addition of Favipiravir in moderately to severely ill COVID-19 patients was cost-savings over SC. Favipiravir was associated with a higher probability of discharging patients alive and lower daily spending on hospitalization than SC.
format Online
Article
Text
id pubmed-9930375
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99303752023-02-15 Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals() Alamer, Ahmad Almutairi, Abdulaali R. Halloush, Shiraz Al-jedai, Ahmed Alrashed, Ahmed AlFaifi, Mashael Mohzari, Yahya Almutairi, Malak AlHassar, Fatimah Howaidi, Jude Almutairi, Wedad Abraham, Ivo Alkhatib, Nimer Saudi Pharm J Original Article PURPOSE: We aimed to evaluate the cost effectiveness of Favipiravir treatment versus standard of care (SC) in moderately to severely ill COVID-19 patients from the Saudi healthcare payer perspective. METHODS: We used the patient-level simulation method to simulate a cohort of 415 patients with moderate to severe COVID-19 disease who were admitted to two Saudi COVID-19 referral hospitals: 220 patients on Favipiravir and 195 patients on SC. We estimated the incremental cost-effectiveness ratio (ICER) of Favipiravir versus SC in terms of the probability to be discharged alive from hospital and the mean time in days to discharge one patient alive. The model was performed twice: first, using unweighted, and second, using weighted clinical and economic data. Weighting using the inverse weight probability method was performed to achieve balance in baseline characteristics. RESULTS: In the unweighted model, base case (probabilistic) ICER estimates favored Favipiravir at savings of Saudi Riyal (SAR)1,611,511 (SAR1,998,948) per 1% increase in the probability of being discharged alive. As to mean time to discharging one patient alive, ICERs favored Favipiravir at savings of SAR11,498 (SAR11,125). Similar results were observed in the weighted model with savings using Favipiravir of SAR1,514,893 (SAR2,453,551) per 1% increase in the probability of being discharged alive, and savings of SAR11,989 (SAR11,277) for each day a patient is discharged alive. CONCLUSION: From the payer perspective, the addition of Favipiravir in moderately to severely ill COVID-19 patients was cost-savings over SC. Favipiravir was associated with a higher probability of discharging patients alive and lower daily spending on hospitalization than SC. Elsevier 2023-04 2023-02-15 /pmc/articles/PMC9930375/ /pubmed/36819111 http://dx.doi.org/10.1016/j.jsps.2023.02.003 Text en © 2023 The Author(s)
spellingShingle Original Article
Alamer, Ahmad
Almutairi, Abdulaali R.
Halloush, Shiraz
Al-jedai, Ahmed
Alrashed, Ahmed
AlFaifi, Mashael
Mohzari, Yahya
Almutairi, Malak
AlHassar, Fatimah
Howaidi, Jude
Almutairi, Wedad
Abraham, Ivo
Alkhatib, Nimer
Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals()
title Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals()
title_full Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals()
title_fullStr Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals()
title_full_unstemmed Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals()
title_short Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals()
title_sort cost-effectiveness of favipiravir in moderately to severely ill covid-19 patients in the real-world setting of saudi arabian pandemic referral hospitals()
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930375/
https://www.ncbi.nlm.nih.gov/pubmed/36819111
http://dx.doi.org/10.1016/j.jsps.2023.02.003
work_keys_str_mv AT alamerahmad costeffectivenessoffavipiravirinmoderatelytoseverelyillcovid19patientsintherealworldsettingofsaudiarabianpandemicreferralhospitals
AT almutairiabdulaalir costeffectivenessoffavipiravirinmoderatelytoseverelyillcovid19patientsintherealworldsettingofsaudiarabianpandemicreferralhospitals
AT halloushshiraz costeffectivenessoffavipiravirinmoderatelytoseverelyillcovid19patientsintherealworldsettingofsaudiarabianpandemicreferralhospitals
AT aljedaiahmed costeffectivenessoffavipiravirinmoderatelytoseverelyillcovid19patientsintherealworldsettingofsaudiarabianpandemicreferralhospitals
AT alrashedahmed costeffectivenessoffavipiravirinmoderatelytoseverelyillcovid19patientsintherealworldsettingofsaudiarabianpandemicreferralhospitals
AT alfaifimashael costeffectivenessoffavipiravirinmoderatelytoseverelyillcovid19patientsintherealworldsettingofsaudiarabianpandemicreferralhospitals
AT mohzariyahya costeffectivenessoffavipiravirinmoderatelytoseverelyillcovid19patientsintherealworldsettingofsaudiarabianpandemicreferralhospitals
AT almutairimalak costeffectivenessoffavipiravirinmoderatelytoseverelyillcovid19patientsintherealworldsettingofsaudiarabianpandemicreferralhospitals
AT alhassarfatimah costeffectivenessoffavipiravirinmoderatelytoseverelyillcovid19patientsintherealworldsettingofsaudiarabianpandemicreferralhospitals
AT howaidijude costeffectivenessoffavipiravirinmoderatelytoseverelyillcovid19patientsintherealworldsettingofsaudiarabianpandemicreferralhospitals
AT almutairiwedad costeffectivenessoffavipiravirinmoderatelytoseverelyillcovid19patientsintherealworldsettingofsaudiarabianpandemicreferralhospitals
AT abrahamivo costeffectivenessoffavipiravirinmoderatelytoseverelyillcovid19patientsintherealworldsettingofsaudiarabianpandemicreferralhospitals
AT alkhatibnimer costeffectivenessoffavipiravirinmoderatelytoseverelyillcovid19patientsintherealworldsettingofsaudiarabianpandemicreferralhospitals